Kymriah approval generates questions about cost, access, long-term impact of CAR T-cell therapy – Healio
OncLive |
Kymriah approval generates questions about cost, access, long-term impact of CAR T-cell therapy
Healio The recent FDA approval of tisagenlecleucel T-suspension for the treatment of children and young adults with refractory B-cell precursor acute lymphoblastic leukemia marks the first-ever chimeric antigen receptor (CAR) T-cell therapy approval in the … Monroe Carell Jr. Children’s Hospital at Vanderbilt to offer new cutting-edge treatment for type of pediatric leukemiaWinchester Herald Chronicle |
|
Policeman donates stem cells to leukemia patient
Shanghai Daily (subscription) SIX years ago police officer Xu Miao had an encounter he never forgot. And yesterday it led to him becoming a donator of stem cells in Shanghai. The recipient of his stem cells will be a leukemia patient who lives in south China’s Guangxi Zhuang … |
Winchester Herald Chronicle |
Monroe Carell Jr. Children’s Hospital at Vanderbilt to offer new cutting-edge treatment for type of pediatric leukemia
Winchester Herald Chronicle This novel therapy, a personalized treatment known as chimeric antigen receptor (CAR) T-cell therapy, is an innovative treatment designed for children and young adults with pre-B cell ALL that has come back after treatment (relapsed) or unresponsive to … |
OncLive |
Practical Issues Surrounding Immunotherapy for HNSCC
OncLive Ezra Cohen, MD: Let’s talk about a couple of very practical issues. The first is a patient who has had prior cetuximab, and now you’re thinking about immunotherapy in the form of an anti-PD-1. Is there a reason to think about that patient any … |
Xconomy |
How Bayer and Ginkgo Teamed Up in a $100M Synthetic Biology Bet
Xconomy Nitrogen is essential for plant growth and photosynthesis, but plants can’t pull it directly from air. They rely on bacteria on their roots to convert the gas into a usable form. Many major food crops don’t have these bacteria but Bayer wants to change … |
Renal and Urology News |
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Renal and Urology News The CheckMate-214 trial demonstrated that combined immunotherapy with the checkpoint inhibitors nivolumab and ipilimumab results in superior outcomes—including significantly better objective response rate (ORR), progression-free survival (PFS), and … |
|
Immunotherapy Superior to Sunitinib for Front-Line mRCC Treatment
Renal and Urology News The CheckMate-214 trial demonstrated that combined immunotherapy with the checkpoint inhibitors nivolumab and ipilimumab results in superior outcomes—including significantly better objective response rate (ORR), progression-free survival (PFS), and … |